Welcome to our dedicated page for Marimed news (Ticker: MRMD), a resource for investors and traders seeking the latest updates and insights on Marimed stock.
MariMed Inc. reports news on its multi-state cannabis operating platform, including cultivation, production, branded consumer products and retail dispensaries. Company updates commonly cover financial results, earnings-call schedules, wholesale distribution, branded product activity and retail operations tied to names such as Betty's Eddies, Bubby’s Baked, InHouse, Nature’s Heritage, Vibations and Thrive Dispensary.
Recurring developments also include capital-structure actions, preferred-stock obligations, hemp-derived THC product launches, cannabis regulatory commentary and community initiatives associated with the company's dispensary and brand portfolio.
MariMed (CSE/OTCQB: MRMD) reported second quarter 2026 revenue of $41.9 million, up from $39.5 million a year earlier and the highest quarterly revenue in its history. GAAP gross margin was 39%, while non-GAAP gross margin was 40%. The Company posted a GAAP net loss of $3.6 million versus a $1.4 million loss in Q2 2025, and non-GAAP net loss of $2.4 million versus non-GAAP net income of $0.3 million. Non-GAAP adjusted EBITDA was $3.9 million with a 9% margin, compared with $4.8 million and a 12% margin last year. For the first half of 2026, revenue reached $81.4 million and operating cash flow was $3.2 million, up from $1.6 million in the prior-year period.
Wholesale revenue grew 6% sequentially and retail revenue 7% sequentially, with branded product distribution expanding to 85% of available storefronts on a trailing 12‑month basis. Cash, cash equivalents and restricted cash totaled $8.4 million at June 30, 2026, total assets were $197.2 million, and total liabilities $147.1 million.
MariMed (CSE:MRMD, OTCQB:MRMD) is launching limited-edition autumn cannabis edibles across its core markets. The company is introducing Betty’s Eddies™ Perk Up, Pumpkin Spice Latte Swirl fruit chews and bringing back Bubby’s Baked™ Pumpkin Bread Bites, positioned around strong consumer demand for seasonal pumpkin flavors.
The Perk Up chews feature a pumpkin spice latte taste and an uplifting blend of 5mg THC, 5mg CBC, and 5mg CBG per piece. Bubby’s Baked Pumpkin Bread Bites are made with real pumpkin and warm spices, each infused with a precise full-spectrum cannabis dose. According to MariMed, these products will be available for adult-use and medical consumers at its Thrive Dispensaries and select retailers in Massachusetts, Maryland, Delaware, Illinois, and, for the Perk Up chews, select Maine dispensaries.
MariMed (CSE: MRMD, OTCQB: MRMD) announced it will report its second quarter 2026 financial results on August 12, 2026 after market close. Management will hold a conference call on August 13, 2026 at 8:00 a.m. EDT to discuss the results, with a live webcast and playback available via the company’s Investor Relations website.
MariMed (MRMD), through its Betty’s Eddies brand, introduced Betty’s Bite-A-Mins, a daily wellness chew combining full-spectrum cannabis, 30mg of CBD, and the recommended daily allowance of vitamins C, D3, and Zinc in a tropical smoothie flavor. The new chews will be sold at MariMed’s Thrive Dispensary locations and other licensed cannabis retailers across Massachusetts, Maryland, Illinois, Delaware, Maine, and Rhode Island, expanding the brand’s core lineup of effect-focused cannabis fruit chews.
MariMed (CSE/OTCQB: MRMD) brand Nature’s Heritage launched “The Nose Knows,” a science-backed cannabis consumer education campaign. It teaches shoppers to choose products by aroma rather than THC percentage, grouping strains into six aroma-and-effect categories and using immersive in-store experiences plus an online “Find Your Flower” quiz.
MariMed (MRMD) announced it has submitted applications to the DEA to register certain state-licensed medical cannabis operations. This registration is required to qualify for protections linked to cannabis’ federal rescheduling to Schedule III, including federal safe harbor and relief from IRS Section 280E restrictions.
MariMed (MRMD) reported first quarter 2026 revenue of $39.5 million, up from $37.9 million in 2025. GAAP net loss was $3.8 million, with non-GAAP net loss of $3.2 million. Non-GAAP adjusted EBITDA was $3.6 million, a margin of 9%.
The company also restructured $14.725 million of Series B preferred stock, extending the weighted average maturity to 4.6 years and removing a February 26, 2026 mandatory conversion date, which it says reduces near-term refinancing risk and supports liquidity.
MariMed (CSE: MRMD; OTCQB: MRMD) will report first quarter 2026 financial results on May 13, 2026 after market close. Management will host a conference call on May 14, 2026 at 8:00 a.m. EDT with a live webcast and on‑demand playback on the company investor relations site.
MariMed (CSE: MRMD, OTCQX: MRMD) reported fourth-quarter and full-year 2025 results: 2025 revenue $159.8M, sixth consecutive year of positive adjusted EBITDA, and wholesale sales up 11%. GAAP net loss widened to $14.5M while non-GAAP adjusted EBITDA was $16.9M. The company expanded distribution to 85% of dispensaries in core markets and completed a restructuring that extends Series B maturities to a weighted average of 4.6 years, improving near-term liquidity.
MariMed (CSE: MRMD; OTCQX: MRMD) reached a Restructuring and Exchange Agreement to extend and reprofile its $14.725 million Series B Convertible Preferred Stock obligation.
The deal removes a February 28, 2026 mandatory conversion, lengthens weighted average maturity by 4.6 years, and issues a $2.0M note (8% maturing Mar 2028), a $6.0M note (10% maturing Mar 2031), and $6.725M of Series B preferred at $0.25 per share, convertible February 2031.